

## Special Issue

# Male Reproductive Medicine: From Basic to Clinical Research

### Message from the Guest Editor

This Special Issue aims to bridge the gap between foundational scientific discoveries and their translation into clinical practice. By bringing together cutting-edge research from diverse disciplines, this Special Issue seeks to highlight the latest advancements in male reproductive medicine, from molecular and cellular studies to large-scale clinical trials and innovative therapeutic approaches. Topics of interest include, but are not limited to, spermatogenesis, hormonal regulation, genetic and epigenetic influences, environmental toxicology, lifestyle factors, and emerging technologies in diagnostics and treatment.

We invite researchers, clinicians, and experts in the field to share their insights, findings, and perspectives. By fostering interdisciplinary collaboration and knowledge exchange, this Special Issue aspires to advance our understanding of male reproductive health and pave the way for improved diagnostic tools, therapeutic interventions, and patient outcomes. Together, we can address the pressing challenges in male reproductive medicine and contribute to a healthier future for individuals and families worldwide.

---

### Guest Editor

Prof. Dr. Donghui Huang

1. Institute of Reproduction Health Research, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China
2. Shenzhen Huazhong University of Science and Technology Research Institute, Shenzhen 518109, China

---

### Deadline for manuscript submissions

closed (31 October 2025)



## Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.5  
CiteScore 7.8  
Indexed in PubMed



[mdpi.com/si/234480](https://mdpi.com/si/234480)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.5  
CiteScore 7.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.2 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2026).